Literature DB >> 10741738

Overexpression level of stromelysin 3 is related to the lymph node involvement in non-small cell lung cancer.

T J Delebecq1, H Porte, F Zerimech, M C Copin, V Gouyer, E Dacquembronne, M Balduyck, A Wurtz, G Huet.   

Abstract

Proteases contribute to tumor invasion and metastasis via their potential to degrade basement membranes and extracellular matrix. Our aim was to compare the level of several proteases: urokinase-type plasminogen activator (u-PA), matrix metalloproteinase 2 (MMP-2; 72-kDa type IV collagenase, also known as gelatinase A), MMP-11 [also known as stromelysin 3 (STR3)], and cathepsins B and L in resected non-small cell lung cancer. Between June 1996 and March 1998, samples of lung tumor tissues were taken from 119 surgically treated patients. Thirty out of the 119 tumor samples were matched with corresponding adjacent normal tissue. u-PA was measured by a commercially available immunoluminometric assay. Metalloproteinases and cathepsins have been evaluated at the RNA level by Northern blot and quantified with a PhosphorImager. Expression of these proteases was compared to the following clinicopathological parameters: pathological diagnosis, tumor size, exposure to asbestos, radiotherapy, neo-adjuvant chemotherapy, tumor-node-metastasis stage, lymph node involvement, presence of metastasis. u-PA, MMP-2, MMP-11/STR3, and cathepsin B were significantly increased in tumor (the tumor:normal ratio was on average increased by 5.4-, 2.2-, 83.5-, and 2.2-fold, respectively). The tumor:normal ratio of MMP-11/ STR3 was found to be significantly linked to the lymph node involvement (P < 0.05). Our results suggest that several proteases are involved in the invasive potential of non-small cell lung cancer and that the quantification of MMP-11/ STR3 could represent an useful prognostic marker.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10741738

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  9 in total

1.  MMP-10 is overexpressed, proteolytically active, and a potential target for therapeutic intervention in human lung carcinomas.

Authors:  Jason H Gill; Ian G Kirwan; Jill M Seargent; Sandie W Martin; Sidiq Tijani; Vladimir A Anikin; Alan J Mearns; Michael C Bibby; Alan Anthoney; Paul M Loadman
Journal:  Neoplasia       Date:  2004 Nov-Dec       Impact factor: 5.715

2.  Toll-Like Receptor 4 and Matrix Metalloproteases 11 and 13 as Predictors of Tumor Recurrence and Survival in Stage II Colorectal Cancer.

Authors:  Noemi Eiro; Juan Francisco Carrión; Sandra Cid; Alejandro Andicoechea; José Luis García-Muñiz; Luis O González; Francisco J Vizoso
Journal:  Pathol Oncol Res       Date:  2019-02-01       Impact factor: 3.201

3.  Effect of the expression of matrix metalloproteases and their tissue inhibitors on survival of patients with resectable colorectal cancer.

Authors:  Lucía González; Noemí Eiró; Luis O González; Alejandro Andicoechea; Esther Barbón; José L García-Muñiz; Francisco J Vizoso
Journal:  Dig Dis Sci       Date:  2012-04-10       Impact factor: 3.199

4.  Matrix metalloproteinase-10 is a critical effector of protein kinase Ciota-Par6alpha-mediated lung cancer.

Authors:  L A Frederick; J A Matthews; L Jamieson; V Justilien; E A Thompson; D C Radisky; A P Fields
Journal:  Oncogene       Date:  2008-04-21       Impact factor: 9.867

5.  Relationship between plasma D-dimer levels and clinicopathologic parameters in resectable colorectal cancer patients.

Authors:  Gang Xu; Ya-Li Zhang; Wen Huang
Journal:  World J Gastroenterol       Date:  2004-03-15       Impact factor: 5.742

6.  Matrix metalloproteinase-10 is required for lung cancer stem cell maintenance, tumor initiation and metastatic potential.

Authors:  Verline Justilien; Roderick P Regala; I-Chu Tseng; Michael P Walsh; Jyotica Batra; Evette S Radisky; Nicole R Murray; Alan P Fields
Journal:  PLoS One       Date:  2012-04-24       Impact factor: 3.240

7.  ETV4 plays a role on the primary events during the adenoma-adenocarcinoma progression in colorectal cancer.

Authors:  Aline Simoneti Fonseca; Anelisa Ramão; Matheus Carvalho Bürger; Jorge Estefano Santana de Souza; Dalila Lucíola Zanette; Greice Andreotti de Molfetta; Luiza Ferreira de Araújo; Rafaela de Barros E Lima Bueno; Graziela Moura Aguiar; Jessica Rodrigues Plaça; Cleidson de Pádua Alves; Anemari Ramos Dinarte Dos Santos; Daniel Onofre Vidal; Gyl Eanes Barros Silva; Rodrigo Alexandre Panepucci; Fernanda Maris Peria; Omar Feres; José Joaquim Ribeiro da Rocha; Marco Antonio Zago; Wilson Araújo Silva
Journal:  BMC Cancer       Date:  2021-03-01       Impact factor: 4.430

8.  Identification of genes down-regulated during lung cancer progression: a cDNA array study.

Authors:  Mara Campioni; Vincenzo Ambrogi; Eugenio Pompeo; Gennaro Citro; Mauro Castelli; Enrico P Spugnini; Antonio Gatti; Pierluigi Cardelli; Laura Lorenzon; Alfonso Baldi; Tommaso C Mineo
Journal:  J Exp Clin Cancer Res       Date:  2008-09-15

9.  Expression of CD147 and matrix metalloproteinase-11 in colorectal cancer and their relationship to clinicopathological features.

Authors:  Xiuyun Tian; Chunxiang Ye; Yongyong Yang; Xiaoya Guan; Bin Dong; Min Zhao; Chunyi Hao
Journal:  J Transl Med       Date:  2015-10-27       Impact factor: 5.531

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.